ipragliflozin + furosemide

**ipragliflozin + furosemide** is a combination of two diuretic agents used experimentally to increase diuresis and manage body fluid overload conditions. **Ipragliflozin** is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that induces osmotic diuresis by promoting renal glucose excretion, leading to increased urinary volume. **Furosemide** is a potent loop diuretic that inhibits sodium-potassium-chloride cotransporters (NKCC2) in the thick ascending loop of Henle, increasing the excretion of sodium, chloride, and other electrolytes, which also results in increased urine output. The combination can enhance overall natriuresis and fluid loss. The mechanism-of-action synergy has been demonstrated in preclinical models, though routine clinical use and fixed-dose combinations do not appear to be marketed or widely approved as of 2025.

Other names

ipragliflozin + furosemide